Clovis Oncology, Inc.

( )
CLVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -0.24%53.330.9%$1405.14m
JNJJohnson & Johnson -0.57%180.970.7%$1371.68m
BMYBristol-Myers Squibb Co. -0.25%76.961.0%$1210.27m
MRKMerck & Co., Inc. -0.17%94.640.7%$1159.77m
ABBVAbbVie, Inc. 0.27%149.631.9%$1108.02m
LLYEli Lilly & Co. -0.10%306.001.1%$917.73m
AZNAstraZeneca Plc -0.41%66.381.0%$504.88m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.11%142.750.0%$479.99m
VERUVeru, Inc. -0.25%12.180.0%$283.31m
NVSNovartis AG -0.37%91.590.2%$266.51m
GSKGlaxoSmithKline Plc -0.14%44.940.2%$252.33m
HZNPHorizon Therapeutics Plc 0.00%88.035.4%$192.26m
NVONovo Nordisk A/S -0.61%107.340.1%$182.00m
SGENSeagen Inc. 0.00%133.475.7%$176.88m
VTRSViatris, Inc. 0.00%11.530.0%$163.21m

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.